# US 7,745,576 B2 · Polypeptides having antimicrobial activity and polynucleotides encoding same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,745,576 B2 - Document ID: US7745576B2 - Status: Granted - Kind: B2 - Application number: 11/509,859 - Filed: 2006-08-25 - Published: 2008-09-04 - Granted: 2010-06-29 - Earliest claimed: 2005-08-26 - Assignees: Novozymes Adenium Biotech A/S - Inventors: Nikolaj Spodsberg - Web page: https://patentgrep.com/patent/US7745576B2 ## CPC - C07K 14/43536: {from worms} - A23K 20/147: Polymeric derivatives, e.g. peptides or proteins - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A23K: FODDER - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. ## Claims ### Claim 1 An isolated polypeptide having antimicrobial activity, selected from the group consisting of: (a) a polypeptide with at least 80% sequence identity with amino acids 1 to 21 of SEQ ID NO: 2; (b) a polypeptide which is encoded by a polynucleotide which hybridizes under high stringency conditions with (i) nucleotides 496 to 558 of SEQ ID NO: 1,(ii) the cDNA sequence contained in nucleotides 1 to 558 of SEQ ID NO: 1, or (iii) a complementary strand of (i) or (ii); and (c) a polypeptide which is a fragment of the sequence of amino acids 1 to 21 of SEQ ID NO: 2, which has antimicrobial activity. ### Claim 2 (depends on 1) The polypeptide of claim 1, with at least 80% identity with amino acids 1 to 21 of SEQ ID NO: 2. ### Claim 3 (depends on 1) The polypeptide of claim 1, with at least 85% identity with amino acids 1 to 21 of SEQ ID NO: 2. ### Claim 4 (depends on 1) The polypeptide of claim 1, with at least 90% identity with amino acids 1 to 21 of SEQ ID NO: 2. ### Claim 5 (depends on 1) The polypeptide of claim 1, with at least 95% identity with amino acids 1 to 21 of SEQ ID NO: 2. ### Claim 6 (depends on 1) The polypeptide of claim 1, comprising the sequence of amino acids 1 to 21 of SEQ ID NO: 2. ### Claim 7 (depends on 1) The polypeptide of claim 1, consisting of the sequence of amino acids 1 to 21 of SEQ ID NO: 2. ### Claim 8 (depends on 1) The polypeptide of claim 1, which is a fragment of the sequence of amino acids 1 to 21 of SEQ ID NO: 2, which has antimicrobial activity. ### Claim 9 (depends on 1) The polypeptide of claim 1, which is encoded by a polynucleotide which hybridizes under high stringency conditions with (i) nucleotides 496 to 558 of SEQ ID NO: 1, (ii) the cDNA sequence contained in nucleotides 1 to 558 of SEQ ID NO: 1, or (iii) a complementary strand of (i) or (ii). ### Claim 10 (depends on 1) A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable vehicle. ### Claim 11 (depends on 1) An animal feed comprising a polypeptide of claim 1. ### Claim 12 (depends on 1) A method for killing or inhibiting growth of microbial cells comprising contacting the microbial cells with a polypeptide of claim 1.